FAST NEWS: CStone Revenue Doubles, Helping Company Pare Losses
The latest: CStone Pharmaceuticals (2616.HK) announced on Thursday it expects to report its revenue doubled to 475 million yuan ($70 million) or more last year, while its net loss narrowed…
CStone Finds Tonic in Steady Stream of Drug Approvals, Licensing Deals
Cancer drug specialist reported its first significant revenue in 2020, following a string of milestones capped by a $200 million investment from Pfizer Key takeaways: Strong upfront licensing fees helped…